Company: RGNX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0000950170-25-069237
Chunk: 1

Company: REGENXBIO Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 shares authorized, no shares issued   and outstanding at March 31, 2025 and December 31, 2024

     —

     —

     Common stock; $0.0001 par value; 100,000 shares authorized at March 31, 2025    and December 31, 2024; 50,117 and 49,549 shares issued and outstanding at    March 31, 2025 and December 31, 2024, respectively

     5

     5

     Additional paid-in capital

     1,201,020

     1,192,536

     Accumulated other comprehensive loss

     (762
     )

     (741
     )

     Accumulated deficit

     (926,066
     )

     (932,149
     )

     Total stockholders’ equity

     274,197

     259,651

     Total liabilities and stockholders’ equity
      
     $
     490,929

     $
     465,989

The accompanying notes are an integral part of these unaudited consolidated financial statements.